Acquisitions13 May 2026, 08:41 pm
Zydus to Acquire Assertio Holdings for $166.4 Million
AI Summary
Zydus Lifesciences' subsidiary, Zydus Worldwide DMCC, will acquire all outstanding shares of Assertio Holdings for $23.50 per share in cash, totaling approximately $166.4 million. The acquisition will provide Zydus with an immediate U.S. specialty oncology commercial footprint. Assertio is a U.S.-based pharmaceutical company focused on specialty and oncology supportive-care therapies, listed on Nasdaq (ASRT). The transaction, approved by both companies' boards, is structured as a tender offer followed by a merger and is subject to customary closing conditions and regulatory approvals. The acquisition is expected to be completed in the financial year 2026-27.
Key Highlights
- Zydus Lifesciences to acquire Assertio Holdings for $166.4 million.
- Acquisition provides Zydus with a U.S. oncology commercial footprint.
- Assertio's shares will be acquired for $23.50 per share in cash.
- Transaction structured as a tender offer followed by a merger.
- Acquisition expected to close in financial year 2026-27.